Angiex, Inc.
Angiex is dedicated to developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality and deliver safe and effective cancer therapies. Their mission is to exploit novel biology to gain revolutionary power over cancer, aiming to make cancer a non-lethal disease. Based in Cambridge, Massachusetts, Angiex was founded by experts in angiogenesis, vascular biology, and oncology. Their lead product, AGX101, is progressing through clinical trials, with a pipeline of additional ND-ADCs in development.
Industries
Nr. of Employees
small (1-50)
Angiex, Inc.
150 CambridgePark Drive, 5th floor, Cambridge, MA 02140
Patents
Products
Lead TM4SF1-directed nuclear-delivered antibody-drug conjugate (lead ND-ADC)
A first-in-class antibody–drug conjugate designed to target the TM4SF1 cell-surface transporter expressed on tumor cells and tumor vasculature and to deliver a cytotoxic payload into the nucleus or cytosol.
Lead TM4SF1-directed nuclear-delivered antibody-drug conjugate (lead ND-ADC)
A first-in-class antibody–drug conjugate designed to target the TM4SF1 cell-surface transporter expressed on tumor cells and tumor vasculature and to deliver a cytotoxic payload into the nucleus or cytosol.
Services
Discovery-to-IND preclinical activities including target validation, potency assays, xenograft efficacy studies, and safety/pharmacology experiments.
Design and execution support for Phase I open-label dose-escalation and expansion clinical trials to evaluate safety, pharmacokinetics, and preliminary anti-tumor activity.
Management and coordination of outsourced bioconjugation and cGMP manufacture of clinical trial material through contract manufacturing partners.
Discovery-to-IND preclinical activities including target validation, potency assays, xenograft efficacy studies, and safety/pharmacology experiments.
Design and execution support for Phase I open-label dose-escalation and expansion clinical trials to evaluate safety, pharmacokinetics, and preliminary anti-tumor activity.
Management and coordination of outsourced bioconjugation and cGMP manufacture of clinical trial material through contract manufacturing partners.
Expertise Areas
- Antibody-drug conjugate development
- Target discovery and validation (TM4SF1)
- Oncology preclinical models and in vivo efficacy
- Intracellular/nuclear delivery strategies
Key Technologies
- Antibody-drug conjugation
- Nuclear delivery / intracellular trafficking assays
- In vitro potency assays
- Human tumor xenograft models
News & Updates
Angiex has reached a milestone by dosing the first patient in its Phase 1 clinical trial for AGX101, a TM4SF1-directed antibody-drug conjugate targeting solid tumors. The trial assesses safety, pharmacokinetics, and anti-tumor activity, with the potential to treat aggressive cancers.
The FDA has cleared the IND application for Angiex's lead product, AGX101, enabling the company to begin Phase 1 clinical trials.
Angiex's research in vascular biology and cancer was highlighted in the Wall Street Journal, emphasizing its innovative approach targeting TM4SF1 in solid tumors.
Angiex was featured in Labiotech’s guide on building successful biotech startups, highlighting the importance of Cambridge’s biotech ecosystem.
Angiex is featured in Drug Discovery World as a leading North American biotech innovator, with CEO Paul Jaminet discussing the role of Cambridge’s infrastructure.
Abzena supports Angiex’s Phase I trial by supplying clinical trial materials for AGX101, a novel therapy targeting tumor blood vessels.
Angiex has reached a milestone by dosing the first patient in its Phase 1 clinical trial for AGX101, a TM4SF1-directed antibody-drug conjugate targeting solid tumors. The trial assesses safety, pharmacokinetics, and anti-tumor activity, with the potential to treat aggressive cancers.
The FDA has cleared the IND application for Angiex's lead product, AGX101, enabling the company to begin Phase 1 clinical trials.
Angiex's research in vascular biology and cancer was highlighted in the Wall Street Journal, emphasizing its innovative approach targeting TM4SF1 in solid tumors.
Angiex was featured in Labiotech’s guide on building successful biotech startups, highlighting the importance of Cambridge’s biotech ecosystem.
Angiex is featured in Drug Discovery World as a leading North American biotech innovator, with CEO Paul Jaminet discussing the role of Cambridge’s infrastructure.
Abzena supports Angiex’s Phase I trial by supplying clinical trial materials for AGX101, a novel therapy targeting tumor blood vessels.